Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires
First launches expected in H1 2022
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
Subscribe To Our Newsletter & Stay Updated
